Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Calpain system protein expression in basal-like and triple-negative invasive breast cancer.

Storr SJ, Lee KW, Woolston CM, Safuan S, Green AR, Macmillan RD, Benhasouna A, Parr T, Ellis IO, Martin SG.

Ann Oncol. 2012 Sep;23(9):2289-96. doi: 10.1093/annonc/mds176. Epub 2012 Jun 27.

2.

[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].

Liu H, Fan QH, Zhang ZH, Li X, Yu HP, Liu GZ, Meng FQ.

Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8. Chinese.

PMID:
19489221
4.

IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype.

Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A.

Hum Pathol. 2009 Nov;40(11):1528-33. doi: 10.1016/j.humpath.2009.05.005. Epub 2009 Aug 19.

PMID:
19695680
5.

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.

Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, Katsumata N, Kinoshita T, Takiguchi Y, Tanzawa H, Fujiwara Y.

Breast Cancer Res Treat. 2012 Apr;132(3):793-805. doi: 10.1007/s10549-011-1554-7. Epub 2011 May 12.

PMID:
21562709
6.

Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer.

Aleskandarany MA, Green AR, Benhasouna AA, Barros FF, Neal K, Reis-Filho JS, Ellis IO, Rakha EA.

Breast Cancer Res. 2012 Jan 6;14(1):R3.

7.
8.

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

De Brot M, Rocha RM, Soares FA, Gobbi H.

Pathology. 2012 Jun;44(4):303-12. doi: 10.1097/PAT.0b013e3283534bcb.

PMID:
22544210
9.

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.

Karihtala P, Kauppila S, Soini Y, Arja-Jukkola-Vuorinen.

BMC Cancer. 2011 Jun 21;11:262. doi: 10.1186/1471-2407-11-262.

10.

Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer.

Baker BG, Ball GR, Rakha EA, Nolan CC, Caldas C, Ellis IO, Green AR.

Breast Cancer Res Treat. 2013 Jan;137(1):127-37. doi: 10.1007/s10549-012-2302-3. Epub 2012 Dec 4.

PMID:
23208589
11.

Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.

Zhao P, Lu Y, Jiang X, Li X.

Cancer Sci. 2011 May;102(5):1107-11. doi: 10.1111/j.1349-7006.2011.01894.x. Epub 2011 Feb 28.

12.
13.

Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype.

Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y.

Breast Cancer Res Treat. 2013 Feb;138(1):81-90. doi: 10.1007/s10549-013-2442-0. Epub 2013 Feb 15.

PMID:
23412770
14.

Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.

Kurebayashi J, Kanomata N, Yamashita T, Shimo T, Mizutoh A, Moriya T, Sonoo H.

Breast Cancer. 2015 May;22(3):292-9. doi: 10.1007/s12282-013-0478-y. Epub 2013 Jun 8.

PMID:
23749689
15.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
16.

Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis.

Taliano RJ, Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E.

Hum Pathol. 2013 Dec;44(12):2743-50. doi: 10.1016/j.humpath.2013.07.021.

17.

Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F.

BMC Cancer. 2011 Jul 15;11:299. doi: 10.1186/1471-2407-11-299.

18.

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.

Nofech-Mozes S, Trudeau M, Kahn HK, Dent R, Rawlinson E, Sun P, Narod SA, Hanna WM.

Breast Cancer Res Treat. 2009 Nov;118(1):131-7. doi: 10.1007/s10549-008-0295-8. Epub 2009 Feb 3.

PMID:
19189211
19.

Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.

Milde-Langosch K, Karn T, Müller V, Witzel I, Rody A, Schmidt M, Wirtz RM.

Breast Cancer Res Treat. 2013 Jan;137(1):57-67. doi: 10.1007/s10549-012-2296-x. Epub 2012 Nov 8.

PMID:
23135572
20.

A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.

Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.

Breast Cancer Res Treat. 2011 Nov;130(2):489-98. doi: 10.1007/s10549-011-1709-6. Epub 2011 Aug 12.

PMID:
21837481

Supplemental Content

Support Center